Serum IL-23 levels have demonstrated greater potential for the diagnosis of IBD than dedicated inflammatory biomarkers such as FCal (fecal calprotectin), CRP (C-reactive protein), and albumin. This evidence concerns the gene IL37 and inflammatory bowel disease.